Live News EARNINGS M impact Jun 22, 2026, 09:26 AM UTC

MLTX Reports Sonelokimab Results

MoonLake announces week 52 results of sonelokimab from its phase 3 VELA program in hidradenitis suppurativa

SQUAWKNEWS Updated Jun 22, 2026, 09:26 AM UTC

MLTX - MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026